School of Food and Bioengineering, Henan University of Science and Technology
Luoyang, Henan, 471000, China
NCT Number: NCT06680102
Assessing the clinical efficacy of weizmannia coagulans BC99 in alleviating allergic rhinitis symptoms, improving gut microbiota, and reducing adverse reactions in patients.
Looking for future studies?
Notify Me18 year–65 year
All sexes
Interventional
Not applicable
Luoyang, Henan, 471000, China
Healthy volunteers accepted: Yes
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
The experimental phase of this study lasts for 8 weeks, with each patient making three visits at weeks 1, 4, and 8.
The experimental phase of this study lasts for 8 weeks, with each patient making three visits at weeks 1, 4, and 8.
Time frame: 8 weeks
Improvement in Nasal symptoms was assessed using the Total Nasal Symptom Score(TNSS), which included four common nasal symptoms: itchiness, nasal congestion, sneezing, and runny nose. The four symptoms were scored using a "four-point scale", that is, according to the severity of each symptom from 0 to 3 points, that is, the higher the score, the more severe the symptoms, and the total score of the entire TNSS score is the sum of the four symptom scores, which ranges from 0 to 12 points.
Time frame: 8 weeks
Changes in subjects' fecal microbiota, including abundance and proportion of beneficial bacteria, were assessed by 16S rRNA sequencing before and after probiotic intervention.
Time frame: 8 weeks
The changes of Immunoglobulin A and Immunoglobulin E before and after intervention were detected by ELISA.
Time frame: 8 weeks
Levels of IL-4, IL-5, IL-10, IL-13.
Wecare Probiotics Co., Ltd.
Industry
The Effectiveness of Weizmannia Coagulans BC99 in Alleviating Allergic Rhinitis in Adults and Its Impact on the Gut Microbiota.
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT03075917
Allergic Rhinitis, Hypersensitivity
Bagnols-sur-Cèze, France
View Trial DetailsNCT05346718
Allergic Rhinitis, Birch Pollen Allergy
Hanover, Lower Saxony, Germany
View Trial DetailsNCT06916884
Allergic Rhinitis, Hypersensitivity
Mexico City, Mexico
View Trial DetailsNCT05476484
Allergic Rhinitis, Allergy
Hørsholm, Copenhagen, Denmark
View Trial Details